We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

54 hedge funds and large institutions have $132M invested in Kiniksa Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 15

5.84% less ownership

Funds ownership: 86.89% → 81.05% (-5.8%)

11% less funds holding

Funds holding: 61 → 54 (-7)

41% less capital invested

Capital invested by funds: $224M → $132M (-$91.4M)

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

Holders
54
Holders Change
-7
Holders Change %
-11.48%
% of All Funds
1.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
25
Reduced
15
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
ACH
ArrowMark Colorado Holdings
Colorado
+$2.89M
2
Victory Capital Management
Victory Capital Management
Texas
+$1.75M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.66M
4
Bank of America
Bank of America
North Carolina
+$1.4M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.16M

Top Sellers

1
VC
Vivo Capital
California
-$11.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.59M
3
First Manhattan
First Manhattan
New York
-$866K
4
FCMI
Foresite Capital Management IV
California
-$866K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$849K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$23.8M – – –
ACH
2
ArrowMark Colorado Holdings
Colorado
$17.4M +$2.89M +261,624 +15%
HA
3
HHLR Advisors
Cayman Islands
$15.9M +$351K +31,734 +2%
DM
4
Deerfield Management
New York
$10.8M -$400K -36,173 -3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$9.93M -$849K -76,851 -6%
BlackRock
6
BlackRock
New York
$9.51M +$120K +10,828 +1%
SI
7
Sofinnova Investments
California
$7.85M – – –
Ameriprise
8
Ameriprise
Minnesota
$5.72M -$822K -74,372 -10%
VMI
9
VHCP Management II
New York
$4.6M -$758K -68,620 -11%
Citadel Advisors
10
Citadel Advisors
Florida
$3.14M -$40.9K -3,697 -1%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$3.09M +$1.66M +150,000 +71%
BC
12
Boxer Capital
California
$2.47M – – –
VMI
13
VHCP Management III
New York
$2.36M -$389K -35,183 -11%
Victory Capital Management
14
Victory Capital Management
Texas
$2.02M +$1.75M +158,776 +203%
State Street
15
State Street
Massachusetts
$1.95M +$103K +9,282 +4%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.41M +$41.9K +3,792 +2%
Northern Trust
17
Northern Trust
Illinois
$1.39M +$95.2K +8,614 +6%
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$1.19M +$1.16M +105,000 +300%
Bank of America
19
Bank of America
North Carolina
$1.15M +$1.4M +126,569 +1,415%
Hudson Bay Capital Management
20
Hudson Bay Capital Management
Connecticut
$1.11M +$166K +15,000 +13%
Morgan Stanley
21
Morgan Stanley
New York
$921K +$532K +48,136 +80%
Goldman Sachs
22
Goldman Sachs
New York
$499K +$493K +44,601 +318%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$445K -$45.9K -4,158 -7%
PPA
24
Parametric Portfolio Associates
Washington
$439K +$221K +19,977 +63%
N
25
Nuveen
North Carolina
$347K +$24.9K +2,251 +6%
1
2 3

KNSA Hedge Fund Activity: Q3 2019 in Review

54 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2019, worth a combined $132M — down 41% from $224M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of KNSA and 3 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 25 added.

The largest buyer was ArrowMark Colorado Holdings, adding an estimated $2.89M. The largest seller was Vivo Capital, exiting entirely with an estimated $11.4M sold.

  • 54 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2019, down from 61 in Q2 2019.
  • Funds reported $132M of Kiniksa Pharmaceuticals stock for Q3 2019, down 41% quarter-over-quarter.
  • 3 funds opened new Kiniksa Pharmaceuticals positions in Q3 2019 and 10 closed out, a net change of -7 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q3 2019 was ArrowMark Colorado Holdings, an estimated $2.89M added.
  • The largest Kiniksa Pharmaceuticals seller in Q3 2019 was Vivo Capital, an estimated $11.4M sold.

Based on aggregated 13F filings for Q3 2019.